Before you leave...
Take 20% off your first order
20% off
Enter the code below at checkout to get 20% off your first order
Discover summer reading lists for all ages & interests!
Find Your Next Read

Provides insights into the drug discovery innovations that are shaping future CNS therapies
In the vast field of neuroscience, drug discovery targeting the central nervous system (CNS) presents both extraordinary opportunities and complex challenges. Disorders such as Alzheimer's disease, schizophrenia, and epilepsy affect millions worldwide, demanding innovative therapeutic strategies. Yet understanding brain processes and overcoming the blood-brain barrier continue to pose significant hurdles for researchers and developers alike.
Trends in CNS Drug Discovery offers a comprehensive overview of the methodologies, successes, and challenges shaping this critical area of pharmaceutical research. Covering a wide range of key areas, from current therapeutic paradigms to emerging technologies, this state-of-the-art volume brings together expertise from leading scientists and drug developers who address the role of cannabinoids and psychedelics in advancing CNS therapeutics, discuss emerging modalities such as protein degraders and allosteric modulators, examine funding strategies and academic-industrial collaborations, highlight advancements in brain-penetrating cancer treatments and other high-impact areas, and more.
A critical reference for academic researchers and industry professionals in medicinal chemistry, pharmaceutical research, and neurobiology, Trends in CNS Drug Discovery is also an ideal resource for graduate-level courses in neuroscience or pharmaceutical sciences.
Author: Dario Doller
ISBN-10: 3527352805
ISBN-13: 9783527352807
Publisher: Wiley-Vch
Language: English
Published: 09/24/2025
Pages: 480
Format: Hardcover
Weight: 2.12lbs
Size: 9.61h x 6.69w x 1.06d
Dario Doller, PhD, has over 30 years of experience in pharmaceutical research, contributing to numerous clinical compounds and a marketed drug. He has authored over 100 articles and patents and is Chief Scientific Officer at Modulate Bio.
Kevin J. Hodgetts, PhD, is Associate Professor of Neurology at Harvard Medical School and Head of Medicinal Chemistry and Director of the Lab for Drug Discovery in Neuroscience (LDDN) at Brigham and Women's Hospital.
Thanks for subscribing!
This email has been registered!
Take 20% off your first order
Enter the code below at checkout to get 20% off your first order